1. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.
- Author
-
Schubert, M.-L., Schmitt, M., Wang, L., Ramos, C.A., Jordan, K., Müller-Tidow, C., and Dreger, P.
- Subjects
- *
CHIMERIC antigen receptors , *T cells , *CD19 antigen , *B cell tumors , *CANCER treatment , *ANTINEOPLASTIC agents , *DRUG side effects , *NEUROTOXICOLOGY - Abstract
Chimeric antigen receptor (CAR) T cells directed against the B-cell marker CD19 are currently changing the landscape for treatment of patients with refractory and/or relapsed B-cell malignancies. Due to the nature of CAR T cells as living drugs, they display a unique toxicity profile. As CAR T-cell therapy is extending towards other diseases and being more broadly employed in hematology and oncology, optimal management strategies of side-effects associated with CAR T-cell therapy are of high relevance. Cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and cytopenias constitute challenges in the treatment of patients with CAR T cells. This review summarizes the current understanding of CAR T-cell toxicity and its management. • CAR T cells are associated with unique side-effects. • Cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) and cytopenias are common. • Understanding the presentation, pathophysiology, grading and management of side-effects is crucial for CAR T-cell safety. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF